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Abstract: Bisphosphonates, pyrophosphate analogs which potently inhibit osteoclastic bone
resorption, are now firmly established as first-line therapy for osteoporosis. Several
bisphosphonates of varying antiresorptive potency are either in clinical use or well advanced
in clinical trials. Alendronate and risedronate are agents of choice at present because data
from randomized controlled trials demonstrate that each of these nitrogen (N)-containing-
bisphosphonates reduces the incidence of vertebral and nonvertebral fractures by about 50%,
whereas evidence for antifracture efficacy is limited to the vertebral site currently for other
bisphosphonates such as etidronate and ibandronate. There have not been direct studies
comparing the antifracture efficacy of alendronate with that of risedronate. Intermittent
administration of bisphosphonates is now a well established clinical practice, and the potent
bisphosphonate zoledronate produces suppression of bone resorption for at least 12 months
after a single intravenous dose. Future research will better define how to optimally administer
these agents to maximize efficacy and patient compliance. The place in osteoporosis
therapeutics of combining bisphosphonate therapy with agents that primarily stimulate bone
formation, such as parathyroid hormone, remains to be defined.
Keywords: osteoporosis, fracture, bisphosphonates, bone resorption
Introduction
Osteoporosis is an important public health problem that contributes substantially to
morbidity and mortality in an ageing world population. Bone loss is virtually universal
in older people and results in osteoporotic fractures in more than 50% of women,
and almost 1 in 3 men. Bone loss and a consequent increase in risk of fragility fracture
also accompany a variety of disease states (nutritional, endocrinological, and
inflammatory) and therapies (glucocorticoids, organ transplantation). As the world
population ages, the prevalence of osteoporosis is likely to increase, making fracture
prevention one of the principal health concerns of our time.
In the past decade, substantial progress has been made in the pharmacological
prevention of osteoporotic fractures, which is currently dominated by the
bisphosphonate class of drugs. Several members of this group of agents are either in
clinical use or well advanced in clinical trials. This review will focus on differences
in potency, route of administration, duration of action, and efficacy between members
of this expanding class of drugs. It is important to acknowledge at the outset that
only very limited data are available from head-to-head studies of bisphosphonates,
and none at all from clinical studies with fracture as a primary end point, meaning
that inferences about preferred agents must be drawn with caution.
Antiresorptive potency and mechanisms of action
Bisphosphonates are pyrophosphate analogs which contain a phosphate-carbon-
phosphate (P-C-P) core structure that targets them to bone and renders them resistant
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to enzymatic degradation. The initial observations that the
bisphosphonate structure had high affinity for bone and
inhibited degradation of hydroxyapatite crystals led to
confirmation that they could inhibit bone resorption in vitro
(Fleisch et al 1969; Francis et al 1969). Manipulation of the
composition of the side-chains attached to the P-C-P core,
in particular the introduction of a basic nitrogen atom in an
alkyl chain, led to the generation of compounds with
increased antiresorptive potency (Russell et al 1999). Of
the currently available bisphosphonates, etidronate and
clodronate are non-Nitrogen (N)-containing-bisphos-
phonates (which do not contain nitrogen atoms in the side-
chains), whose antiresorptive potency is at the lower end of
the scale, while pamidronate, alendronate, risedronate,
Ibandronate, and zoledronate are N-containing-bisphos-
phonates which exhibit antiresorptive potencies 100–10 000-
fold that of etidronate (Russell et al 1999).
The chemical structure of the bisphosphonates allows
them to bind to mineralized bone surfaces, following which
they are taken up by osteoclasts during bone resorption.
Within these cells, N-containing-bisphosphonates inhibit
key enzymes in the mevalonate pathway. Intermediate
metabolites of this pathway are necessary for prenylation
of intracellular proteins that control the trafficking of key
regulatory proteins to the cell membrane (Rogers 2004).
With this loss of protein prenylation, osteoclasts undergo
apoptosis. This process also occurs in osteoclast precursors,
blocking their development into bone resorbing cells (Van
Beek et al 2002). In contrast, non-N-containing-
bisphosphonates are metabolized to form analogues of
adenosine triphosphate (ATP), which interfere with the
mitochondrial adenosine diphosphate (ADP)/ATP
translocase, and also results in osteoclast apoptosis
(Lehenkari et al 2002).
Bisphosphonate deposited on the bone surface may
remain there for many years and become incorporated into
the structure of bone (Masarachia et al 1996; Bauss and
Russell 2004). This long duration of action opens the
possibility of intermittent administration, which has been
one of the important developments in the field of
bisphosphonate therapeutics in recent years (see frequency
of administration). The reduction in bone turnover caused
by bisphosphonates results in an increased lifespan of
skeletal tissue, providing a longer time in which the
secondary mineralization of bone can proceed (Boivin and
Meunier 2002). This increase in mineral density may
contribute to the greater strength of bisphosphonate-treated
bone (Borah et al 2000), as may the preservation of
trabecular thickness and trabecular connectivity (Borah et
al 2004).
Route of administration
All bisphosphonates are very poorly absorbed from the
gastrointestinal tract (1%–2% of administered dose). The
low bioavailability of orally administered bisphosphonates
is a critical issue in their use. They must be taken fasting, or
with water alone if they are to be absorbed at all. Fasting
for 30 minutes after dosing is adequate in most
circumstances, but a 60-minute fast increases the effect
of ibandronate on bone density by 60% (Tanko et al 2003).
N-containing-bisphosphonates can cause upper
gastrointestinal irritation by directly inducing mucosal
injury, so patients must not lie down for 30–60 minutes after
oral dosing to prevent reflux of the tablet into the esophagus.
N-containing-bisphosphonates cannot be used in those with
anatomical or motility disorders of the upper gastrointestinal
tract (Lanza 2002). The less potent, non-N-containing-
bisphosphonates, such as etidronate and clodronate, appear
to have better upper gastrointestinal tolerability, but still need
to be taken fasting to optimize bioavailability.
One way of circumventing the low bioavailability of
bisphosphonates, precluding upper gastrointestinal toxicity,
and ensuring patient compliance, is to administer the drug
parenterally. This approach has been taken with
pamidronate, ibandronate, and zoledronate. Pamidronate
was originally developed as an oral preparation, which was
withdrawn because of concerns about gastrointestinal
toxicity (Lufkin et al 1994). Currently the intravenous
preparation of pamidronate is less commonly used for
treatment of osteoporosis than in the management of
humoral hypercalcemia of malignancy. Ibandronate has been
studied in both oral and intravenous forms (Chesnut et al
2004; Recker et al 2004), while zoledronate is being
developed as an intravenous therapy. Intravenous adminis-
tration of potent bisphosphonates can be expeditiously
achieved in an outpatient setting (Pecherstorfer et al 1996;
Reid et al 2002). Clearly, parenteral administration is
associated with the additional costs of medical personnel
and equipment, but these may be offset by the need for less
frequent dosing (discussed in Frequency of administration).
No compelling evidence for antifracture efficacy of
intravenous bisphosphonates has yet been published,
although intramuscular administration of clodronate reduces
vertebral fracture risk in glucocorticoid-treated patients
(Frediani et al 2003).Therapeutics and Clinical Risk Management 2006:2(1) 79
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Frequency of administration
Intermittent dosing of bisphosphonates (less frequent
administration than traditional daily dosing) has been part
of clinical practice for some time. The original studies of
fracture prevention using etidronate employed a dosing
regimen that involved cyclical therapy with daily
administration for 2 weeks every 3 months, ie, 4 cycles of
therapy each year (Storm et al 1990). The rationale for this
approach was the recognition that continuous therapy with
this first-generation bisphosphonate was associated with a
risk of impaired mineralization (osteomalacia). Osteo-
malacia is not a complication of therapy with other
bisphosphonates in clinical use. However, the recognition
that currently prescribed bisphosphonates may persist on
the bone surface for considerable periods of time has led to
a widespread use of intermittent dosing in clinical practice.
For the oral N-containing-bisphosphonates risedronate and
alendronate, this has meant a move from daily ingestion to
weekly administration of a dose equivalent to 7 times the
standard daily dose. Although no trials were undertaken to
confirm the antifracture efficacy of weekly therapy with
either alendronate or risedronate, comparative studies
demonstrated equivalent increases in bone density and
suppression of biochemical markers of bone resorption in
response to weekly versus daily administration of each drug
(Brown et al 2002; Rizzoli et al 2002). Weekly adminis-
tration of each of these agents reduces the disruption of the
patient’s morning routine by the requirement to take the
bisphosphonate in advance of eating.
Ibandronate administered by mouth either daily (2.5 mg)
or intermittently (20 mg every other day for 12 doses every
3 months) (Chesnut et al 2005) produces equivalent
increases in bone density and protection against vertebral
fractures, but low-dose intermittent intravenous ibandronate
administration (0.5–1 mg every 3 months) did not reduce
fracture risk, presumably because either the administered
dose was inadequate, or the dosing interval was too long to
maintain suppression of bone resorption (Recker et al 2004).
These data attest to the importance of careful optimization
of both dose and dosing frequency in investigating the
antifracture efficacy of bisphosphonates. Further
investigation of intermittent ibandronate therapy, using
monthly administration, is in progress (Miller et al 2005).
Recent results from a phase II study of the potent
bisphosphonate zoledronate suggest that intravenous
administration of this agent as infrequently as once each
year may be an effective therapy for osteoporosis. Thus, in
postmenopausal women, a single intravenous dose of 4 mg
zoledronate produced changes in bone density 1 year later
that were equivalent to those observed in women treated
with lower doses of the same agent more frequently (Reid
et al 2002), and comparable with those seen in response to
potent oral N-containing-bisphosphonates. Markers of bone
turnover remained suppressed at the end of the 1 year follow-
up period. Phase 3 studies of the effect of annual
administration of zoledronate on the incidence of fragility
fractures are nearing completion.
It is therefore now clear that intermittent administration
of potent bisphosphonates (oral or parenteral) is both feasible
and efficacious. This mode of therapy appears to be preferred
by patients (Simon et al 2002) and may be associated with
improved compliance with long-term therapy (Cramer et al
2005). Daily administration of these agents is already
receding, and the challenge now is to optimize dosing
intervals for maximum patient acceptability without
compromising efficacy.
Antifracture efficacy
A substantial body of evidence has accrued over the past
10–15 years that demonstrates that bisphosphonates prevent
fragility fractures in osteoporotic populations (Table 1).
Potent bisphosphonates usually increase bone density of the
spine by about 5% at 2 years, and reduce levels of
biochemical markers of bone turnover by more than 50%.
By far the largest body of evidence demonstrating
antifracture efficacy has been generated in studies of the
oral N-containing-bisphosphonates risedronate and
alendronate, each of which has been shown to reduce
vertebral and nonvertebral (including hip) fractures by 20%–
50% in postmenopausal women with osteoporosis (Black
et al 1996; Cummings et al 1998; Harris et al 1999; Pols et
al 1999; McClung et al 2001). These findings are confirmed
in meta-analyses (Cranney, Tugwell, et al 2002; Cranney,
Wells, et al 2002), which provide pooled relative risk (RR)
reductions of 27%–49% for vertebral and nonvertebral
fractures for each agent. Estimates of the numbers of patients
at high risk of osteoporotic fracture that need to be treated
over 2 years with alendronate or risedronate to prevent a
vertebral (72 and 96, respectively) or nonvertebral (24 and
43, respectively) are similar for these agents (Cranney,
Guyatt, et al 2002). Trends towards fewer fractures are
apparent within months of initiation of these agents, before
substantial increases in bone density have occurred.
Prevention of vertebral fractures has also been demonstratedTherapeutics and Clinical Risk Management 2006:2(1) 80
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in osteoporotic men treated with alendronate (Orwoll et al
2000), glucocorticoid-treated men taking risedronate (Reid
et al 2001), and in glucocorticoid-treated subjects taking
either risedronate or alendronate (Wallach et al 2000; Adachi
et al 2001). Reanalysis of the pivotal studies with each of
these agents confirm antifracture efficacy in subjects who
are either osteoporotic in terms of bone density or who have
a history of vertebral fractures (Black et al 2000; Heaney et
al 2002), and that this effect is independent of age.
Antivertebral fracture efficacy has also been reported
for ibandronate in postmenopausal women (Chesnut et al
2004), etidronate in postmenopausal women (Storm et al
1990; Cranney, Guyatt, et al 2002), and clodronate in
glucocorticoid-treated subjects (Frediani et al 2003).
However, none of these agents has yet been demonstrated
to prevent nonvertebral fractures, other than in post-hoc
analyses (Chesnut et al 2004). No fracture data are yet
available for intravenous zoledronate, which is currently
undergoing phase III clinical studies.
Most of the data relating to fracture prevention by
bisphosphonates has come from trials of 3 years duration.
These studies leave unanswered the important question of
efficacy and safety with long-term use, and for how long
bisphosphonate therapy should be continued. A 2-year
extension to one of the risedronate studies has been reported,
during which the double-blind and randomization were
maintained (Sorensen et al 2003). The risk of new vertebral
fractures was reduced by 59% in years 4 and 5, compared
with a 49% reduction in the first 3 years. These trends are
reported to continue over a further 2 years of follow-up.
Data to 8–10 years from extensions to the phase 3
alendronate studies have been published (Bone et al 2004;
Ensrud et al 2004). In the extension study of Bone et al
(2004), 10 years of continuous therapy with alendronate
was associated with a steady increase in spinal bone mineral
density (BMD) and stability of BMD at the hip sites, while
women who received alendronate for 5 years and then no
further active treatment experienced stable spine BMD and
a gradual fall in hip BMD over 5 years of follow-up. The
limited fracture data available from this study suggest
ongoing low rates of fracture during the extension phase.
In the FLEX (Fracture Intervention Trial long-term
extension) study, subjects who had completed 5 years of
active alendronate therapy were re-randomized to receive
ongoing active therapy or placebo. After 3 years of follow-
up, bone turnover was lower and bone density at hip and
spine was higher in the subjects assigned to continue
alendronate therapy, but there were clearly persisting effects
on both bone turnover and trabecular bone density in the
group assigned to placebo (Ensrud et al 2004). Unpublished
5 year data from the same study suggest lower rates of
vertebral fracture in the group that continued alendronate
therapy, but no reduction in the rate of nonvertebral fracture
(Black et al 2004). Importantly, no unexpected adverse
events emerged from the long-term risedronate or
alendronate studies.
The available evidence, therefore, supports the use of
either alendronate or risedronate as the preferred
bisphosphonate for treatment of osteoporosis, since each of
these drugs has been shown in randomized controlled trials
to decrease rates of both vertebral and nonvertebral fractures.
Is there any benefit to using either agent in preference to
the other? Two randomized comparisons of the effects of
alendronate and risedronate on bone turnover and bone
density have favored alendronate (Hosking et al 2003; Rosen
et al 2005), but in one of these studies risedronate was
administered suboptimally (Hosking et al 2003) and both
measured surrogate outcomes only. No studies have directly
compared the antifracture efficacies of these two drugs, nor
is it likely that such studies will be performed. It has been
estimated that a study population in excess of 50 000 subjects
would be required to provide sufficient statistical power to
detect a 10% difference between vertebral fracture rates in
an alendronate versus risedronate study (Kanis et al 2002).
In the meta-analyses performed by the ORAG (Osteoporosis
Research Advisory Group) group, the relative risk (RR)
reduction for both vertebral and nonvertebral fractures was
greater in comparison to placebo for alendronate (RR 0.52
and 0.51, respectively) than for risedronate (RR 0.64 and
0.73, respectively), but clearly these studies were performed
in different study populations, making direct comparison
of RR reductions unwise (Cranney, Guyatt, et al 2002). An
attempt to refine a comparison of the alendronate and
risedronate data from the ORAG meta-analyses, using
epidemiological analytic techniques, concluded that
alendronate was superior to all other antiresorptive therapies
(including risedronate) in preventing nonvertebral fractures,
but was not more efficacious than risedronate in reducing
the risk of vertebral fractures (Wehren et al 2004). On the
other hand, a review of antifracture studies that focused on
studies that included intention to treat analyses suggested a
stronger evidence base for efficacy of risedronate in the
prevention of nonvertebral fractures (Boonen et al 2005).
In the absence of conclusive comparative data, and theTherapeutics and Clinical Risk Management 2006:2(1) 83
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presence of evidence of efficacy of each agent, alendronate
and risedronate should be regarded as equally effective in
preventing osteoporotic fractures.
Combination with anabolic
skeletal therapies
The advent of parathyroid hormone (PTH) as an anabolic
agent has enabled systematic evaluation of the effects of
combining treatment with an agent which primarily
stimulates bone formation with bisphosphonates, which
primarily suppress bone resorption. The hope that
combination therapy might confer additive effects on bone
density and fracture risk reduction has not been confirmed
in the clinical studies performed to date. Thus, cotreatment
of osteoporotic postmenopausal women with PTH and
alendronate results in smaller increases in markers of bone
formation and bone density than are seen in subjects treated
with PTH alone (Black et al 2003). A similar blunting of
the effect of PTH on bone density and markers of bone
formation by concomitant exposure to alendronate was
observed in men with low bone density (Finkelstein et al
2003). However, anabolic responses are still observed in
response to initiation of PTH treatment in subjects who have
been taking alendronate for at least 12 months (Ettinger et
al 2004; Cosman et al 2005). Pretreatment with a less potent
antiresorptive agent, such as raloxifene, may be associated
with less blunting of the increase in BMD induced by
subsequent therapy with PTH than is observed when PTH
therapy follows a period of treatment with alendronate
(Ettinger et al 2004). Overall, the available data suggest
that the induction of bone resorption by PTH is an important
determinant of the potency of its anabolic skeletal effect,
and that currently there is no clear-cut rationale for
combining PTH and antiresorptive therapies. An alternative
approach might be to treat with PTH alone for 18–24 months
to achieve substantial increments in bone density, and then
withdraw PTH treatment in favor of antiresorptive therapy
to maintain the increased bone density. Recent evidence
suggests that this sequential approach, in which short-term
PTH treatment is followed by treatment with alendronate,
produces greater increments in bone density than are
observed if PTH treatment is followed by treatment with a
placebo (Black et al 2005). No data are yet available from
studies of combining PTH therapy with other
bisphosphonates, and the place of combination and/or
sequential PTH/bisphosphonate therapy in osteoporosis
management is not yet clear.
Adverse effects
N-containing-bisphosphonates can cause upper gastro-
intestinal irritation and mucosal ulceration, so patients must
not lie down for 30–60 minutes after oral dosing to prevent
reflux of the tablet into the esophagus, and these agents
cannot be used in those with anatomical or motility disorders
of the upper gastrointestinal tract. In other patients, attention
to the dosing regimen outlined above prevents difficulties
in most patients (Lanza 2003). Although there was not
demonstrable upper gastrointestinal toxicity in the placebo-
controlled trials of potent N-containing-bisphosphonates,
post-marketing surveys suggest that up to 10% of patients
prescribed these agents experience such side-effects
(Ettinger et al 1998). Two comparative endoscopic studies
have demonstrated a higher incidence of gastric ulceration
in alendronate-treated subjects than those treated with
risedronate (Lanza et al 2000; Thomson et al 2002), but no
differences were observed between the agents in the
incidence of gastrointestinal adverse events in a 1 year
randomized comparison (Rosen et al 2005).
Intravenous administration of N-containing-bisphos-
phonates necessarily avoids upper gastrointestinal toxicity.
The most common adverse event following parenteral
bisphosphonate administration is a transient, self-limited
myalgic syndrome. This effect occurs in 10%–15% of
zoledronate-treated women (Reid et al 2002). No data are
available from comparative studies that address the
frequency of this side-effect following exposure to different
bisphosphonates.
Muscle and/or bone pain following ingestion of oral
bisphosphonates did not emerge as an adverse event from
randomized controlled trials, but there have been a small
number (in relation to the size of the exposed population)
of reports of severe musculoskeletal discomfort in response
to alendronate and risedronate in post-marketing
surveillance (Wysowski and Chang 2005).
Recently, use of potent bisphosphonate therapy has been
associated with jaw osteonecrosis (Durie et al 2005;
Hellstein and Marek 2005). This poorly characterized and
understood condition is probably attributable to
bisphosphonate therapy, but almost all of the described cases
have occurred in oncology patients receiving high-dose
bisphosphonate therapy for management of metastatic
skeletal disease, often following dental surgical procedures
(Bagan et al 2005; Purcell and Boyd 2005). Several different
bisphosphonates have been implicated in the pathogenesis
of this rare disorder in oncology patients, and someTherapeutics and Clinical Risk Management 2006:2(1) 84
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preliminary data suggest that it may occur more frequently
in patients treated with zoledronate than in those treated
with pamidronate (Durie et al 2005). Jaw osteonecrosis in
patients receiving conventional doses of oral bisphos-
phonates for treatment of osteoporosis is extremely
uncommon.
Summary and conclusion
Bisphosphonates currently dominate the pharmacotherapy
of osteoporosis. Non-N-containing-bisphosphonates such
as etidronate and clodronate have largely been superseded
by the more potent N-containing-bisphosphonates, an
increasing number of which are entering clinical practice.
The long skeletal retention time of these agents allows
intermittent administration, and the most potent drugs may
be effective when administered as infrequently as annually.
At present, the evidence base from randomized controlled
trials with fracture as the primary endpoint supports the
preferential use of either of two oral N-containing-
bisphosphonates, risedronate and alendronate, since each
of these drugs has been shown to reduce the incidence of
both vertebral and nonvertebral fractures. Comparative
studies of risedronate and alendronate have only assessed
adverse events or surrogate efficacy outcomes (bone
resorption and bone density), so there is no clear rationale
for choosing one agent over the other. There is considerable
interest in the outcome of studies that are assessing fracture
incidence in response to intermittent administration of potent
intravenous bisphosphonates such as zoledronate. If these
studies demonstrate antifracture efficacy, the clinician will
have a greater range of proven therapeutic options available
for fracture prevention. In the coming era of anabolic agents
for osteoporosis, it remains to be determined whether any
of the bisphosphonates might confer greater benefits than
other members of the class when used in combination or
sequence with drugs that stimulate bone formation.
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